Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Farmers Insurance
Argus Health
Cerilliant
Harvard Business School
Merck
Covington
US Department of Justice
Fish and Richardson
Boehringer Ingelheim

Generated: January 21, 2018

DrugPatentWatch Database Preview

CAMBIA Drug Profile

« Back to Dashboard

Which patents cover Cambia, and when can generic versions of Cambia launch?

Cambia is a drug marketed by Depomed Inc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-three patent family members in thirty-two countries.

The generic ingredient in CAMBIA is diclofenac potassium. There are forty-seven drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the diclofenac potassium profile page.

US Patents and Regulatory Information for CAMBIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Depomed Inc CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Depomed Inc CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Depomed Inc CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Depomed Inc CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Depomed Inc CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for CAMBIA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Depomed Inc CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 ➤ Subscribe ➤ Subscribe
Depomed Inc CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for CAMBIA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Potassium Oral Solution (Sachet) 50 mg ➤ Subscribe 1/24/2011

Premature patent expiration for: CAMBIA

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
➤ Subscribe CAMBIA ➤ Subscribe

Non-Orange Book US Patents for CAMBIA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,687,542 Rapidly bioavailable tablet and capsule formulations of diclofenac ➤ Subscribe
9,827,197 Diclofenac formulations and methods of use ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for CAMBIA

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Teva
Chubb
Daiichi Sankyo
Moodys
Baxter
US Army
Chinese Patent Office
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot